Literature DB >> 26088955

Antiphospholipid-mediated thrombosis: interplay between type of antibodies and localisation of lung, and cardiovascular incidences in primary antiphospholipid syndrome.

Ljudmila Stojanovich1, Aleksandra Djokovic2, Milica Kontic3.   

Abstract

OBJECTIVES: The aim of this study was to analyse prevalence and type of pulmonary manifestations in patients with primary antiphospholipid syndrome (PAPS), their association to antiphospholipid antibody (aPL) type and localisation of peripheral vascular thrombosis, and possible relationship to existing cardiac manifestations.
METHODS: Our cross-sectional study comprised 318 PAPS patients, enrolled in the study as the Serbian APS Registry. aPL analysis included detection of aCL (IgG/IgM), ß2GPI (IgG/IgM) and LA, served to evaluate associations with cardiac and pulmonary manifestations.
RESULTS: In patients with pulmonary embolism and infarction, we observed significant prevalence of myocardial infarction (p=0.044), unstable angina pectoris (p=0.001), venous thrombosis (p=0.007) arterial thrombosis (p=0.0001), deep venous thrombosis of the low extremities (p=0.008), and superficial thrombophlebitis of the low extremities (p=0.023). Patients with primary pulmonary hypertension were more prone to unstable angina pectoris (p=0.009), while patients with secondary pulmonary hypertension were more prone to venous thrombosis (p=0.04) and deep venous thrombosis of the inferior extremities (p=0.04). Patients with pulmonary microthrombosis were more prone to unstable angina pectoris (p=0.026), arterial thrombosis (p=0.002), venous thrombosis (p=0.001), deep venous thrombosis of the inferior extremities (p=0.001), and superficial thrombophlebitis of the inferior extremities (p=0.001). The presence of LA was significantly higher in patients with pulmonary embolism and infarction (p=0.001), secondary pulmonary hypertension (p=0.032), and pulmonary microthrombosis (p=0.001).
CONCLUSIONS: Presence of LA was associated with distinct pulmonary manifestations in the Serbian APS cohort. There is a strong link between some cardiovascular and pulmonary manifestations in PAPS patients, suggesting complexity and evolutionary nature of PAPS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26088955

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Natasa Stanisavljevic; Sandra Djokic; Branka Filipovic; Predrag Matic; Milomir Milanovic; Svetlana Apostolovic; Jovica Saponjski
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

2.  Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.

Authors:  Natasa Stanisavljevic; L Stojanovich; D Marisavljevic; A Djokovic; V Dopsaj; J Kotur-Stevuljevic; J Martinovic; L Memon; S Radovanovic; B Todic; D Lisulov
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

3.  Primary antiphospholipid syndrome associated Liebman-Sachs endocarditis leading to diffuse alveolar hemorrhage: A case report.

Authors:  Ryan Hyde; Martin Runnstrom; Austin Anderson; Leonard Riley; Ali Ataya
Journal:  Respir Med Case Rep       Date:  2018-08-24

Review 4.  The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Authors:  Chris Wincup; Yiannis Ioannou
Journal:  Front Pediatr       Date:  2018-11-27       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.